title: [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].
abstract: OBJECTIVE
  To investigate the effects of glucagon-like peptide-1 (GLP-1) on liver oxidative stress, TNF-α and TGF-β1 in rats with diet-induced non-alcoholic fatty liver disease (NAFLD).
  
  
  METHODS
  Thirty male rats were randomly divided into 3 equal groups and fed for 16 weeks with normal diet (ND), high-fat diet (HFD), or high-fat diet with intraperitoneal injection of liraglutide (GLP-1, administered in the later 4 weeks). The rats were then sacrificed to obtain blood samples and liver tissues for analyzing the levels of blood aminotransferase (ALT), triglyceride (TG), and total-cholesterol (TC) using an automatic biochemical analyzer and the levels of superoxide dismutase (SOD), malondial-dehyde (MAD), free fatty acid (FFAs), TNF-α in the liver homogenates and TGF-β1 in serum by radioimmunoassay or ELISA.
  
  
  RESULTS
  Compared with ND group, HFD group showed significantly increased body weight, liver index, serum levels of ALT, TG, TC, and TGF-β1, and TG, TC, MAD, FFAs, and TNF-α in the liver homogenates, with also significantly increased degree of hepatic steatosis and inflammation activity (P<0.05) and lowered level of SOD. All these changes were markedly ameliorated in GLP-1 group (P<0.05).
  
  
  CONCLUSIONS
  Liraglutide can reduce high-fat diet-induced hepatic steatosis, improve oxidative stress and lipid peroxidation, and decrease TGF-β1 and TNF-α levels in serum and liver homogenates, suggesting its potential as a therapeutic agent for NAFLD.
authors.affiliation: Southern Medical University, Guangzhou 510515, China.E-mail: 253154446@qq.com.
authors.forename: Huiting
authors.initials: H
authors.lastname: Gao
authors.forename: Lishu
authors.initials: L
authors.lastname: Xu
authors.forename: Dongfeng
authors.initials: D
authors.lastname: Li
authors.forename: Lichang
authors.initials: L
authors.lastname: Guang
authors.forename: Weiping
authors.initials: W
authors.lastname: Deng
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology; D000069450:Liraglutide / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000097:blood*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D053773:Transforming Growth Factor beta1; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D000069450:Liraglutide; D002784:Cholesterol; D013482:Superoxide Dismutase; D000410:Alanine Transaminase